ralimetinib

Small moleculeexperimental

Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor. — Wikipedia

Clinical trial activity

5 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2008 (NCT01393990)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21
Mol. weight
420.54 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ly2228820
  • ly2228820
  • ly-2228820
  • ly-2228820
  • ly-22288220
  • ly-22288220
  • ralimetinib
  • ralimetinib
  • ralimetinib
  • ralimetinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02860780Phase 1Aug 1, 2016Eli Lilly
NCT02364206Phase 1/Phase 2 (Phase 2)Jun 1, 2015Centre Jean Perrin, Fondation ARC, National Cancer Institute, France
NCT02322853Phase 2Jan 1, 2015Fondation ARC, National Cancer Institute, France, University of Caen-Normandie
NCT01663857Phase 1/Phase 2 (Phase 2)Jul 1, 2012Eli Lilly
NCT01393990Phase 1Aug 1, 2008Eli Lilly
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit3322008
Fondation ARCAcademic/Hospital2012015
National Cancer Institute, FranceGovernment2012015
Centre Jean PerrinAcademic/Hospital1112015
University of Caen-NormandieAcademic/Hospital1112015
5 organizations
Page 1 / 1